SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the design, manufacture, and launch of rockets and spacecrafts. It provides satellite communication services. The company was founded by Elon Reeve Musk on March 14, 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is generating massive market buzz following its high-profile public debut, with investors deeply divided over whether the company's multi-trillion dollar valuation reflects revolutionary long-term potential or unsustainable hype. The community is actively debating the stock's future, as traders closely monitor high volatility and look ahead to upcoming options trading, index inclusion, and the potential impact of insider lock-up expirations.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as the community closely monitors the progress of its $110 billion acquisition of Warner Bros. Discovery following the Department of Justice's approval. Shareholders are actively debating the potential for long-term synergy value, the impact of ongoing regulatory reviews in Europe, and the strategic implications of management's integration plans while remaining focused on upcoming deal closing milestones.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is trending following a Bloomberg report that the streaming company is exploring a potential sale, with discussions reportedly underway with at least one major U.S. media entity. The community is actively debating the credibility of these buyout rumors and the company's long-term strategic value, leading to significant volatility as traders analyze the potential for a premium acquisition against the backdrop of an increasingly competitive streaming landscape.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

ARS Pharmaceuticals is trending as its competitor Aquestive Therapeutics faces a regulatory setback regarding their Anaphylm treatment, solidifying SPRY's position as the sole provider of an FDA-approved, needle-free epinephrine solution. Investors are actively discussing the potential for a significant short squeeze given the stock's high short interest and the removal of near-term competitive pressure.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as the stock surges following a major announcement that it is breaking ground on an expanded multi-billion dollar semiconductor packaging campus in Arizona. The community is actively discussing this expansion as a key play on domestic semiconductor onshoring and the growing necessity of advanced packaging to support the AI supply chain.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors debate the potential for future adoption versus extreme price volatility and frustration over a lack of major updates from the Flexa team. While community sentiment is heavily polarized between long-term holders citing the utility of the Anvil and Flexa ecosystem and critics pointing to the token's persistent downward trend, active discussions remain focused on legislative catalysts like the CLARITY Act and alleged institutional activity in staking pools.

Entrepreneurshares Series Trust - ERShares Private-Public Crossover ETF

Investors are expressing frustration over the ETF's lack of upward momentum despite its concentrated holding in SpaceX, with many in the community debating the impact of the fund's SPV-based valuation structure versus direct equity exposure. Discussions focus on whether the market is discounting the fund's private asset holdings ahead of a broader public launch or if the current price action reflects concerns regarding transparency and the fund's long-term growth potential.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean Ltd. is currently trending as investors weigh strong backlog growth and improved operational efficiency against geopolitical uncertainty in the Strait of Hormuz. The community is actively debating whether the stock's recent performance is tethered more to daily fluctuations in oil prices or the long-term potential of its merger with Valaris and ongoing debt reduction efforts.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors await the first full commercial revenue report for YARTEMLEA, with the community actively debating whether the company can meet high expectations following its recent FDA approval and partnership deals. Discussion is dominated by speculation over whether recent price volatility is driven by institutional shakeouts ahead of upcoming EMA regulatory decisions or by ongoing short interest as the company shifts into a commercial-stage growth phase.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

TROLL is capturing significant community attention as investors position it alongside established meme coins, with many touting its long-standing cultural relevance and potential for exponential growth. Enthusiasm is centered on the project's ownership of original IP rights and active grassroots campaigns aimed at driving massive adoption within the broader meme ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Day One Biopharmaceuticals, Inc. $DAWN Shares Bought by GC Wealth Management RIA LLC

GC Wealth Management RIA LLC lifted its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 200.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 150,030 shares of the company's stock after acquir...

Day One Biopharmaceuticals (DAWN) Projected to Post Earnings on Tuesday

Day One Biopharmaceuticals (NASDAQ:DAWN) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at...

Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Day One Biopharmaceuticals to a "hold" rating in a research note on Saturday...

Servier completes the acquisition of Day One Biopharmaceuticals

Servier completes the acquisition of Day One Biopharmaceuticals Servier completes the acquisition of Day One Biopharmaceuticals PR Newswire SURESNES, France, April 23, 2026 Acquisition...

Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year High - What's Next?

Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 12-Month High - What's Next...

150,925 Shares in Day One Biopharmaceuticals, Inc. $DAWN Acquired by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA acquired a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the fourth quarter, according to the company in its most recent...

Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High  - Here's What Happened

Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 52-Week High - Time to Buy...

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Rating of "Hold" from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have received a consensus rating of "Hold" from the ten ratings firms that are currently covering the company, MarketBeat...

Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?

Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders? Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, April 9, 2026 Insiders may stand to...

Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High - What's Next?

Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High - What's Next...

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

DAWNDay One Biopharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DAWN News